LIXTE BIOTECHNOLOGY HOLDINGS INC
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
NMAD$3.57-0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED FINANCIAL STATEMENTS
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
(INCLUDING REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM)
| Page Number | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 572) | F-2 |
|---|---|
| Consolidated Balance Sheets – December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Operations – Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Stockholders’ Equity – Years Ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows – Years Ended December 31, 2023 and 2022 | F-7 |
| Notes to Consolidated Financial Statements – Years Ended December 31, 2023 and 2022 | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.